iCAD Corp (ICAD) - Gross Profit Rate

Official company branding of iCAD (ICAD)

iCAD, Inc. (ICAD) bases its business on the implementation of AI algorithms for early breast cancer diagnosis, which streamlines the workflow for radiologists. The gross margin ratio demonstrates the pace of profitability recovery, while 84.40 captures the current value of the indicator. Stable cloud capacity and regular software upgrades eliminate server depreciation. The high accuracy of its solutions allows the company to maintain pricing power over its products for clinics.

ICAD iCAD, Inc. Gross Profitability (07/04/2022 - 08/02/2025)

Comprehensive metric breakdowns and analytics for iCAD, Inc. (ICAD)

- stock quotes and analyst forecast:
- market capitalization indicators:
Fundamental valuation:ICAD - iCAD, Inc.
Core merchandise of iCAD Corp

Gross margin serves as a fundamental efficiency filter, determining the profit share after deducting direct production costs. Analyzing the gross profit level relative to revenue allows for an assessment of management's ability to control cost of goods sold and counter resource inflation. For iCAD, Inc. (ICAD), this indicator reflects the profitability of the synergy between AI diagnostics and radiation therapy hardware systems when supplied to medical centers.

Direct competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Return on Gross Profit HALO|Gross Profitability RVMD|Return on Gross Profit AAPG (Ascentage)|Return on Gross Profit cgoncology.com CGON|UroGen Pharma - Return on Gross Profit|Gross Profit Rate BCAX|PSNL - Gross Profitability|Return on Sales by Gross Profit Erasca Oncology ERAS|delcath.com (DCTH) - Gross Profitability|Y-mAbs Therapeutics - Gross Profit Rate|AURA (Aura Biosciences Inc) - Gross Margin|Gross Profit Margin candeltx.com CADL|Gross Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Gross Profit Rate|Gross Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Gross Profitability|TuHURA Biosciences Inc. - Gross Margin|TARA - Gross Margin|FATE (Fate Therapeutics) - Return on Gross Profit|Return on Gross Profit Aadi Bioscience, Inc.|Return on Gross Profit TCRX|Gross Profitability CSBR|Gross Margin XBIT|Return on Sales by Gross Profit CEL-SCI Corp.|Gross Profitability ostherapies.com OSTX|RADX: Gross Return on Sales|ARTV: Return on Gross Profit|ANL (Adlai Nortye) - Gross Return on Sales|Veru (VERU) - Gross Profitability|Return on Gross Profit Tempest Therapeutics Inc|Gross Profitability Xilio Therapeutics|Gross Return on Sales RENB (Renovaro Inc.)|Gross Profitability Mural Oncology PLC (MURA)|Gross Margin Kairos Pharma (KAPA)|Gross Profitability onkuretherapeutics.com OKUR|GDTC: Gross Return on Sales|CRIS: Return on Gross Profit|apollomicsinc.com (APLM) - Return on Gross Profit|THAR: Gross Margin|Return on Gross Profit Advanced Biomed Inc.|Return on Gross Profit GNPX|Gross Return on Sales CLDI (Calidi Biotherapeutics)|Gross Margin SBFM|Xenetic Biosciences, Inc. - Gross Return on Sales|Gross Profitability Salarius Pharmaceuticals SLRX|Gross Margin purple-biotech.com PPBT|AONC - Gross Profitability|BGNE: Gross Profitability|CKPT: Gross Margin|Elevation Oncology - Gross Profit Rate|Return on Gross Profit IKNA|Gross Margin notablelabs.com|Return on Gross Profit VIRX (Viracta Therapeutics Inc.)|MOR - Gross Profit Margin|Gross Profitability NAYA Biosciences NAYA|AAPGV - Return on Gross Profit